Cholesterol conjugated oligonucleotide and LNA: A comparison of cellular and nuclear uptake by Hep2 cells enhanced by Streptolysin-O

Molecular and Cellular Biochemistry

Volumn 276, Issue 1-2, 2005, Pages 61-69

  Holasová, Šárka ^a   Mojžíšek, Martin ^b   Bunček, Martin ^a   Vokurková, Doris ^c   Radilová, Hana ^a   Šafářová, Martina ^a   Červinka, Miroslav ^b   Haluza, Radovan ^a  

^a GENERI BIOTECH sro   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Gene theraphy; LNA; Oligonucleotide; Uptake

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FLUORESCENT DYE; LOCKED NUCLEIC ACID; OLIGONUCLEOTIDE CHOLESTEROL CONJUGATE; STREPTOLYSIN O; UNCLASSIFIED DRUG;

ARTICLE; CELL KINETICS; CELL PERMEABILIZATION; CELL STRAIN 3T3; CELL STRAIN HEPG2; CELLULAR DISTRIBUTION; CONJUGATION; CULTURE MEDIUM; DRUG DELIVERY SYSTEM; DRUG UPTAKE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONVIRAL GENE DELIVERY SYSTEM;

BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT; CELL LINE; CELL NUCLEUS; CELLS, CULTURED; CHOLESTEROL; CYTOPLASM; FLOW CYTOMETRY; HUMANS; MICROSCOPY, FLUORESCENCE; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; STREPTOLYSINS;

MAMMALIA;

EID: 24144445718     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-005-2912-8     Document Type: Article

References (23)

1. Jendis J, Strack B, Volkmann S, Boni J, Molling K: Inhibition of replication of fresh HIV type 1 patient isolates by a polypurine tract-specific self-complementary oligodeoxynucleotide. Aids Res Human Retroviruses 12: 1161-1168, 1996
2. Helene C, Giovannangeli C, Guieysse-Peugeot AL, Praseuth D: Sequence-specific control of gene expression by antigene and clamp oligonucleotides. Ciba Foundation Symposium 209: 94-102; Discussion 102-106, 1997
3. Astriab-Fisher A, Fisher MH, Juliano R, Herdewijn P: Increased uptake of antisense oligonucleotides by delivery as double stranded complexes. Biochem Pharmacol 68: 403-407, 2004 10.1016/j.bcp.2004.03.040
4. Los M, Burek CJ, Stroh C, Benedyk K, Hug H, Mackiewicz A: Anticancer drugs of tomorrow: Apoptotic pathways as targets for drug design. Drug Discov Today 8: 67-77, 2003 10.1016/S1359-6446(02)02563-1
5. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75: 280-284, 1978 75545
6. Behe MJ: An overabundance of long oligopurine tracts occurs in the genome of simple and complex eukaryotes. Nucleic Acids Res (Online) 23: 689-695, 1995
7. Vasquez KM, Narayanan L, Glazer PM: Specific mutations induced by triplex-forming oligonucleotides in mice. Science 290: 530-533, 2000 10.1126/science.290.5491.530
8. Seidman MM, Glazer PM: The potential for gene repair via triple helix formation. J. Clin. Invest 112: 487-494, 2003 10.1172/JCI200319552
9. de Diesbach P, N'Kuli F, Berens C, Sonveaux E, Monsigny M, Roche AC, Courtoy PJ: Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: Evidence for non-conventional intracellular trafficking. Nucleic Acids Res 30: 1512-1521, 2002 10.1093/ nar/30.7.1512
10. Escude C, Giovannangeli C, Sun JS, Lloyd DH, Chen JK, Gryaznov SM, Garestier T, Helene C: Stable triple helices formed by oligonucleotide N3′-> P5′ phosphoramidates inhibit transcription elongation. Proceedings of the National Academy of Sciences of the United States of America 93: 4365-4369, 1996
11. Torigoe H: Thermodynamic and kinetic effects of N3′-> P5′ phosphoramidate modification on pyrimidine motif triplex DNA formation. Biochemistry 40: 1063-1069, 2001 10.1021/bi001895v
12. Petersen M, Wengel J: LNA: A versatile tool for therapeutics and genomics. Trends Biotechnol 21: 74-81, 2003 10.1016/S0167-7799(02)00038-0
13. Vester B, Wengel J: LNA (locked nucleic acid): High-affinity targeting of complementary RNA and DNA. Biochemistry 43: 13233-13241, 2004 15491130
14. Bhakdi S, Tranum-Jensen J, Sziegoleit A: Mechanism of membrane damage by streptolysin-O. Infect Immun 47: 52-60, 1985 3880730
15. Barry ELR, Gesek FA, Friedman PA: Introduction of antisense by oligonucleotides into cells by permeabilization with streptolysin O. Biotechniquies 15: 1017-1020, 1993
16. Spiller DG, Giles RV, Grzybowski J, Tidd DM, Clark RE: Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: A comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation. Blood 91: 4738-4746, 1998 9616172
17. J Sambrook DW Russell 2001 Molecular Cloning (A Laboratory Manual) Cold Spring Harbor Laboratory Press, Cold Spring Harbor New York
18. Dokka S, Rojanasakul Y: Novel non-endocytic delivery of antisense oligonucleotides. Adv Drug Deliv Rev 44: 35-49, 2000 10.1016/ S0169-409X(00)00082-X
19. Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S: The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 6: 303-315, 2001 10.1016/S1359-6446(00)00326-3
20. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV: Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA 86: 6454-6458, 1989 2549537
21. Wu-Pong S, Weiss TL, Hunt CA: Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res Dev 4: 155-163, 1994 7849486
22. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T, Broberger C, Porreca F, Lai J, Ren K, Ossipov M, Koshkin A, Jakobsen N, Skouv J, Oerum H, Jacobsen MH, Wengel J: Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 97: 5633-5638, 2000 10.1073/pnas.97.10.5633
23. Wingens M, van Hooijdonk CA, de Jongh GJ, Schalkwijk J, van Erp PE: Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes. Arch Dermatol Res 290: 119-125, 1998 10.1007/s004030050276